Cigna vs Cencora
CI and COR side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CI and COR compare
Cigna is the larger company, worth 1.2 times as much as Cencora ($79.7B against $66.8B).
On earnings, Cigna is cheaper: it trades at 13.3× trailing earnings, against 26.0× for Cencora.
Cigna grew revenue faster over the last twelve months (6.8% versus 5.1% for Cencora).
Cigna keeps more of each dollar of sales as profit, with a net margin of 2.1% compared with 0.79% at Cencora.
Both pay dividends: Cigna yields 2.1% and Cencora 0.69%.
Cigna scores higher on the StockData Score (16 against 14 for Cencora), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CI | COR |
|---|---|---|
| Size and price | ||
| Market cap | $79.7B | $66.8B |
| Share price | $301.45 | $349.88 |
| Change, 1 year | 16.8% | −4.1% |
| Change, 5 years | 43.2% | 190% |
| Beta (5Y) | 0.34 | 0.33 |
| Employees | 68K | 51K |
| StockData Score | ||
| Total score | 16 (better) | 14 |
| Valuation score | 6 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 3 | 5 (better) |
| Health score | 2 | 2 |
| Dividend score | 3 | 4 (better) |
| Valuation | ||
| P/E | 13.3× (better) | 26.0× |
| P/S | 0.3× | 0.2× (better) |
| P/B | 1.8× (better) | 21.9× |
| EV/EBITDA | 8.2× (better) | 18.6× |
| P/FCF | – | 16.4× |
| PEG | 11.23 | – |
| FCF yield | – | 6.1% |
| Fair value | $383.88 | $286.64 |
| Margin of safety | 21.5% (better) | −22.1% |
| Growth | ||
| Revenue growth (TTM) | 6.8% (better) | 5.1% |
| Revenue growth, 5Y average | 11.4% (better) | 11.1% |
| Net income growth (TTM) | – | 38.3% |
| EPS growth (TTM) | −0.04% | 38.6% (better) |
| EPS growth, 5Y average | −0.69% | – |
| Profitability | ||
| Gross margin | 20.7% (better) | 4.0% |
| Operating margin | 3.4% (better) | 0.91% |
| Net margin | 2.1% (better) | 0.79% |
| FCF margin | – | 1.2% |
| Return on equity | 14.1% | 104% (better) |
| Return on invested capital | 11.4% | 22.3% (better) |
| Financial health | ||
| Debt / equity | 0.72 (better) | 3.84 |
| Net debt / EBITDA | 1.88 (better) | 2.18 |
| Interest coverage | 7.1× | – |
| Current ratio | 0.84 | 0.93 (better) |
| Altman Z-score | 2.83 | 4.69 (better) |
| Piotroski F-score | 7 | 7 |
| Dividends and buybacks | ||
| Dividend yield | 2.1% (better) | 0.69% |
| Payout ratio | 27.2% | 17.8% |
| Years of dividend growth | 5 | 16 (better) |
| Dividend growth, 5Y average | 173% (better) | 5.8% |
| Buyback yield | 1.7% (better) | 1.5% |
| Shareholder yield | 3.7% (better) | 2.2% |
| Ownership | ||
| Held by institutions | 89.9% | 96.1% |
| Held by insiders | 0.41% | 5.4% |
| Insider net buying, 12 months | −$66.8M | −$11.2M (better) |
| Superinvestors holding | 4 | – |
| Short interest, % of float | 2.4% | 1.7% |
Go deeper
- CI stock overview
- CI income statement
- CI valuation and score
- COR stock overview
- COR income statement
- COR valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.